| P50 | author | Henrik Zetterberg | Q6252048 |
| P2093 | author name string | Samantha C Burnham | |
| P2860 | cites work | Guidelines for the standardization of preanalytic variables for blood-based biomarker studies in Alzheimer's disease research | Q24289435 |
| | Blood-Based Proteomic Biomarkers of Alzheimer's Disease Pathology | Q26774743 |
| | Recent advances in the application of metabolomics to Alzheimer's Disease | Q26828606 |
| | A blood based 12-miRNA signature of Alzheimer disease patients | Q27499741 |
| | Multivariate protein signatures of pre-clinical Alzheimer's disease in the Alzheimer's disease neuroimaging initiative (ADNI) plasma proteome dataset | Q28730795 |
| | Plasma biomarkers of brain atrophy in Alzheimer's disease | Q28741028 |
| | Hypoxia due to cardiac arrest induces a time-dependent increase in serum amyloid β levels in humans | Q28741472 |
| | A blood-based screening tool for Alzheimer's disease that spans serum and plasma: findings from TARC and ADNI | Q28741766 |
| | Evaluation of plasma proteomic data for Alzheimer disease state classification and for the prediction of progression from mild cognitive impairment to Alzheimer disease | Q30571328 |
| | Relationship between plasma analytes and SPARE-AD defined brain atrophy patterns in ADNI | Q31110973 |
| | Evaluation of a previously suggested plasma biomarker panel to identify Alzheimer's disease | Q34141675 |
| | A blood-based predictor for neocortical Aβ burden in Alzheimer's disease: results from the AIBL study | Q34341870 |
| | Plasma based markers of [11C] PiB-PET brain amyloid burden | Q34427001 |
| | Plasma proteins predict conversion to dementia from prodromal disease | Q34556953 |
| | A serum protein-based algorithm for the detection of Alzheimer disease | Q34755504 |
| | Inflammatory proteins in plasma are associated with severity of Alzheimer's disease | Q34769550 |
| | Five out of 16 plasma signaling proteins are enhanced in plasma of patients with mild cognitive impairment and Alzheimer's disease | Q35028860 |
| | Association of plasma clusterin concentration with severity, pathology, and progression in Alzheimer disease | Q35034130 |
| | Identification of preclinical Alzheimer's disease by a profile of pathogenic proteins in neurally derived blood exosomes: A case-control study | Q35085348 |
| | Brain amyloidosis ascertainment from cognitive, imaging, and peripheral blood protein measures | Q35106592 |
| | Validation of a serum screen for Alzheimer's disease across assay platforms, species, and tissues | Q35456060 |
| | Modeling of pathological traits in Alzheimer's disease based on systemic extracellular signaling proteome. | Q35497573 |
| | Longitudinal Protein Changes in Blood Plasma Associated with the Rate of Cognitive Decline in Alzheimer's Disease. | Q50553594 |
| | A blood-based, 7-metabolite signature for the early diagnosis of Alzheimer's disease. | Q50963694 |
| | A Decade of Blood Biomarkers for Alzheimer's Disease Research: An Evolving Field, Improving Study Designs, and the Challenge of Replication. | Q51760901 |
| | Alzheimer disease. | Q51777215 |
| | Identifying early markers of Alzheimer's disease using quantitative multiplex proteomic immunoassay panels. | Q53305742 |
| | Plasma metabolite profiles of Alzheimer's disease and mild cognitive impairment. | Q53351047 |
| | Lifestyle interventions to prevent cognitive impairment, dementia and Alzheimer disease | Q57022760 |
| | Neurofilaments as biomarkers in neurological disorders | Q57588817 |
| | A proposed metabolic strategy for monitoring disease progression in Alzheimer's disease | Q57972006 |
| | microRNA diagnostic panel for Alzheimer's disease and epigenetic trade-off between neurodegeneration and cancer | Q58618681 |
| | Plasma Amyloid as Prescreener for the Earliest Alzheimer Pathological Changes | Q59843503 |
| | Biomarkers for tau pathology. | Q64952063 |
| | Plasma phospho-tau181 increases with Alzheimer's disease clinical severity and is associated with tau- and amyloid-positron emission tomography | Q88296166 |
| | Circulating microRNAs as novel biomarkers of Alzheimer's disease | Q88814899 |
| | Fluid and PET biomarkers for amyloid pathology in Alzheimer's disease | Q90407547 |
| | Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes | Q92103818 |
| | Metabolome in progression to Alzheimer's disease | Q35844155 |
| | Altered lysosomal proteins in neural-derived plasma exosomes in preclinical Alzheimer disease | Q35850718 |
| | Plasma multianalyte profiling in mild cognitive impairment and Alzheimer disease | Q36183810 |
| | Plasma 24-metabolite Panel Predicts Preclinical Transition to Clinical Stages of Alzheimer's Disease | Q36272443 |
| | Plasma proteomics for the identification of Alzheimer disease | Q36767124 |
| | Blood protein predictors of brain amyloid for enrichment in clinical trials? | Q36926754 |
| | Plasma β-amyloid in Alzheimer's disease and vascular disease | Q36949501 |
| | Plasma tau levels in Alzheimer's disease | Q36998625 |
| | Blood Protein Markers of Neocortical Amyloid-β Burden: A Candidate Study Using SOMAscan Technology | Q37044150 |
| | Plasma Phospholipid and Sphingolipid Alterations in Presenilin1 Mutation Carriers: A Pilot Study | Q37091714 |
| | Blood metabolite markers of preclinical Alzheimer's disease in two longitudinally followed cohorts of older individuals | Q37100094 |
| | Inflammatory biomarkers are associated with total brain volume: the Framingham Heart Study | Q37379665 |
| | Plasma tau in Alzheimer disease | Q37384690 |
| | Plasma phospholipids identify antecedent memory impairment in older adults. | Q37714213 |
| | Profile of 6 microRNA in blood plasma distinguish early stage Alzheimer's disease patients from non-demented subjects | Q37725397 |
| | Blood and plasma-based proteomic biomarker research in Alzheimer's disease | Q38022421 |
| | Use of proteomic methods in the analysis of human body fluids in Alzheimer research | Q38060574 |
| | Neurofilament light chain protein as a marker of neuronal injury: review of its use in HIV-1 infection and reference values for HIV-negative controls | Q38734471 |
| | CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis | Q38805517 |
| | Markers of neuroinflammation associated with Alzheimer's disease pathology in older adults | Q38978904 |
| | Identification of a blood-based biomarker panel for classification of Alzheimer's disease | Q39763684 |
| | Association of Plasma Total Tau Level With Cognitive Decline and Risk of Mild Cognitive Impairment or Dementia in the Mayo Clinic Study on Aging | Q40129154 |
| | Prognostic serum miRNA biomarkers associated with Alzheimer's disease shows concordance with neuropsychological and neuroimaging assessment. | Q40231224 |
| | Plasma gelsolin and matrix metalloproteinase 3 as potential biomarkers for Alzheimer disease | Q41086639 |
| | Quantification of plasma phosphorylated tau to use as a biomarker for brain Alzheimer pathology: pilot case-control studies including patients with Alzheimer's disease and down syndrome. | Q41600844 |
| | Amyloid-β sequester proteins as blood-based biomarkers of cognitive decline | Q42026180 |
| | Combination of plasma tumor necrosis factor receptors signaling proteins, beta-amyloid and apolipoprotein E for the detection of Alzheimer's disease | Q43465439 |
| | Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins | Q44917427 |
| | Serum neurofilament light in familial Alzheimer disease: A marker of early neurodegeneration | Q47165587 |
| | Blood-based protein biomarkers for diagnosis of Alzheimer disease | Q47378944 |
| | Amyloid β concentrations and stable isotope labeling kinetics of human plasma specific to central nervous system amyloidosis | Q47572013 |
| | Identification of a small set of plasma signalling proteins using neural network for prediction of Alzheimer's disease | Q47665108 |
| | Assay of Plasma Phosphorylated Tau Protein (Threonine 181) and Total Tau Protein in Early-Stage Alzheimer's Disease. | Q47835205 |
| | Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up | Q47958225 |
| | Membrane-associated forms of the beta A4 amyloid protein precursor of Alzheimer's disease in human platelet and brain: surface expression on the activated human platelet | Q48094420 |
| | Association of Plasma Neurofilament Light With Neurodegeneration in Patients With Alzheimer Disease | Q48243501 |
| | Identification of blood biomarkers for use in point of care diagnosis tool for Alzheimer's disease. | Q48276501 |
| | A candidate plasma protein classifier to identify Alzheimer's disease | Q48609726 |
| | Blood-based biomarkers in Alzheimer disease: Current state of the science and a novel collaborative paradigm for advancing from discovery to clinic | Q49135523 |
| | Plasma lipids metabolism in mild cognitive impairment and Alzheimer's disease | Q50041775 |
| | High performance plasma amyloid-β biomarkers for Alzheimer's disease | Q50107488 |
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | Alzheimer's disease | Q11081 |
| | biomarker | Q864574 |
| P304 | page(s) | 26 | |
| P577 | publication date | 2019-03-28 | |
| P1433 | published in | Molecular Brain | Q6895938 |
| P1476 | title | Blood-based molecular biomarkers for Alzheimer's disease | |
| P478 | volume | 12 | |